Hyperliquid Strategies Inc (PURR) Stock Price, Quote & News

Company Profile

Hyperliquid Strategies Inc. operates as a digital asset treasury company focused on the blockchain and cryptocurrency sector. The company provides investors exposure to the HYPE token through treasury management strategies, such as token accumulation, staking, and yield optimization within the Hyperliquid ecosystem. The company was incorporated in 2025 and is based in New York, New York.

Industry: Capital Markets

Sector: Financial Services

Phone: 212-883-4330

Website: www.hypestrat.xyz

Address:

477 Madison Avenue, 22nd Floor, New York, United States

TonyG6ix Jul. 15 at 1:34 PM

$PURR in it, added.

1 · Reply

Donald_Kerabatsos Jul. 15 at 1:00 PM

$HYPE.X $PURR Sent the A Team in with legal representation. This is how you lead https://www.tradingview.com/news/99Bitcoins:99db4c01d094b:0-hyperliquid-s-lawyers-just-met-the-sec-crypto-unit-here-s-what-happened/

0 · Reply

Donald_Kerabatsos Jul. 15 at 12:53 PM

$HYPE.X $PURR https://x.com/RyanWatkins_/status/2077238121880523027?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

0 · Reply

Olivia_Strickland Jul. 15 at 10:09 AM

$PURR grinding higher premarket, 7.67 after a 7.35 close. no read yet on what's behind the gap. these early moves either build a base or hand it all back, if 7.35 cracks on a pullback I'd bet this fills before lunch. what my scanner just flagged: https://tapeboard.com/go/st/scanner?utm_source=stocktwits&utm_medium=post&utm_campaign=olivia&utm_content=purr-pm-up-scanner&utm_term=scanner&s=PURR

2 · Reply

Thelonius_Stonk Jul. 15 at 9:59 AM

$PURR wutchn

2 · Reply

24_7Markets Jul. 15 at 9:46 AM

$HYPE.X $PURR $BTC.X Chart last 24 hours

1 · Reply

24_7Markets Jul. 15 at 9:45 AM

$HYPE.X $PURR $BTC.X

0 · Reply

Donald_Kerabatsos Jul. 15 at 3:06 AM

$HYPE.X $PURR She took her Viagra tonight…

0 · Reply

vu_jade Jul. 15 at 2:47 AM

$PURR $HYPE.X ADD

0 · Reply

Jackie_Treehorn Jul. 15 at 12:18 AM

$PURR

0 · Reply

Defiance Launches PUR: The First 2X Long PURR ETF

PUR

2026-07-01T19:50:11.000Z - 13 days ago

Hyperliquid Strategies management to meet with Oppenheimer

2026-06-29T20:20:21.000Z - 15 days ago

Hyperliquid Strategies to be added to Russell 3000, 2000, S&P Global BMI Indices

Jun 29, 2026, 4:15 PM EDT - 15 days ago

Hyperliquid Strategies Inc Added to the Russell 3000, Russell 2000 and S&P Global BMI Indices

Jun 25, 2026, 8:00 AM EDT - 20 days ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 16, 2026, 9:00 AM EDT - 4 weeks ago

Hyperliquid Strategies Inc Relaunches Website with Expanded Analytics, HYPE Tokenomics and Insights Sections

Jun 16, 2026, 8:00 AM EDT - 4 weeks ago

Hyperliquid Strategies Registration statement: Registration filing

Jun 4, 2026, 5:46 PM EDT - 5 weeks ago

Hyperliquid Strategies CEO on why he thinks banks are undervaluing SpaceX's IPO

SPCX

May 28, 2026, 7:58 AM EDT - 6 weeks ago

Crypto ETFs: From Bitcoin to Hyperliquid

BHYP FBTC IBIT MSBT MSTR THYP TXXH

May 22, 2026, 8:00 AM EDT - 7 weeks ago

Hyperliquid Strategies Registration statement: Registration filing

2026-05-22T10:05:07.000Z - 7 weeks ago

Hyperliquid Strategies files to sell 35.16M shares of common stock for holders

2026-05-11T12:53:34.000Z - 2 months ago

Hyperliquid Strategies price target raised to $8 from $6 at Cantor Fitzgerald

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Earnings Call Transcript: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Slides: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Quarterly report: Q3 2026

May 7, 2026, 5:00 PM EDT - 2 months ago

Hyperliquid Strategies Earnings release: Q3 2026

2026-05-07T20:47:48.000Z - 2 months ago

Hyperliquid Strategies, Unit Labs announce validator on Hyperliquid

May 7, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended March 31, 2026

May 7, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies and Unit Labs Announce Validator on Hyperliquid

Apr 28, 2026, 4:15 PM EDT - 2 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Fiscal Quarter Ended March 31, 2026

2026-04-24T12:14:26.000Z - 2 months ago

Hyperliquid Strategies initiated with a Buy at Maxim

2026-04-24T12:06:12.000Z - 2 months ago

Hyperliquid Strategies initiated with a Buy at Maxim

Mar 24, 2026, 4:15 PM EDT - 4 months ago

Hyperliquid Strategies Inc. Announces Milestone with Launch of Options Trading on PURR Common Stock

Feb 16, 2026, 7:00 AM EST - 5 months ago

Hyperliquid Strategies Slides: Corporate presentation

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Earnings Call Transcript: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Quarterly report: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Earnings release: Q2 2026

Feb 11, 2026, 8:00 AM EST - 5 months ago

Hyperliquid Strategies Slides: Q2 2026

Feb 11, 2026, 6:45 AM EST - 5 months ago

Hyperliquid Strategies Inc Reports Financial Results for the Quarter Ended December 31, 2025

Feb 5, 2026, 4:15 PM EST - 5 months ago

Hyperliquid Strategies Inc Announces Webcast to Discuss Results for the Quarter Ended December 31, 2025

Dec 8, 2025, 9:20 AM EST - 7 months ago

Hyperliquid Strategies Inc Announces $30 million Stock Repurchase Program

Dec 3, 2025, 5:45 PM EST - 7 months ago

Ex-Barclays CEO unpacks Hyperliquid: ‘The FUTURE of finance'

Dec 2, 2025, 4:30 PM EST - 8 months ago

Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination

Nov 18, 2025, 9:00 AM EST - 8 months ago

Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting

Nov 12, 2025, 7:00 AM EST - 8 months ago

Hyperliquid Strategies Slides: Investor presentation

Oct 22, 2025, 8:00 AM EDT - 9 months ago

Hyperliquid Strategies Registration statement: Registration Filing

Oct 15, 2025, 10:03 AM EDT - 9 months ago

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

Sep 19, 2025, 9:00 AM EDT - 10 months ago

Sonnet to Present at the MedInvest Biotech & Pharma Conference

Aug 11, 2025, 9:15 AM EDT - 1 year ago

Sonnet Releases Virtual Investor "What This Means" Segment

Aug 4, 2025, 8:40 AM EDT - 1 year ago

Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer

Jul 14, 2025, 6:00 AM EDT - 1 year ago

Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy

May 1, 2025, 9:00 AM EDT - 1 year ago

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

Apr 4, 2025, 9:00 AM EDT - 1 year ago

Sonnet's SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

Apr 1, 2025, 4:15 PM EDT - 1 year ago

Sonnet Announces Release of Corporate Update Video

Apr 1, 2025, 7:30 AM EDT - 1 year ago

Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D.

Mar 26, 2025, 9:05 AM EDT - 1 year ago

Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas

Mar 19, 2025, 8:50 AM EDT - 1 year ago

Sonnet BioTherapeutics Receives Notice of Allowance for U.S. Patent Covering Composition of Matter of Specific Amino Acid Substitutions of its IL-18 Binding Protein Resistant Variant Protein

Mar 11, 2025, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 26, 2025, 9:00 AM EST - 1 year ago

Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of Solid Tumors

Feb 19, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

Feb 18, 2025, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

Feb 13, 2025, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Appoints Stephen McAndrew, Ph.D. as Chief Business Officer

Feb 13, 2025, 8:00 AM EST - 1 year ago

Sonnet BioTherapeutics Provides Fiscal Year 2025 First Quarter Business and Earnings Update

Jan 28, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Further Expands Global Intellectual Property Portfolio with Issuance of EU Patent for FHAB® Platform Technology

Jan 22, 2025, 8:35 AM EST - 1 year ago

Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 21, 2025, 9:05 AM EST - 1 year ago

Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas

Dec 23, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment

Dec 17, 2024, 8:50 AM EST - 1 year ago

Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

Dec 9, 2024, 3:42 PM EST - 1 year ago

Sonnet BioTherapeutics Announces $3.9 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Dec 9, 2024, 8:45 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Topline Safety Data Following Successful Completion of SON-1010 Monotherapy Dose Escalation in Phase 1 SB101 Trial

Dec 4, 2024, 9:20 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Publication Detailing the Discovery and Development of SON-1010, an Albumin-Binding IL-12 Fusion Protein, Demonstrating Its Mechanism of Action

Nov 12, 2024, 9:15 AM EST - 1 year ago

Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment

Nov 6, 2024, 1:20 PM EST - 1 year ago

Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq Rules

Nov 6, 2024, 8:30 AM EST - 1 year ago

Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates

Oct 17, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq

Oct 9, 2024, 8:45 AM EDT - 1 year ago

Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India

Oct 4, 2024, 8:30 AM EDT - 1 year ago

Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs

Sep 30, 2024, 9:00 AM EDT - 1 year ago

Sonnet BioTherapeutics Announces Launch of CEO Corner Platform

TonyG6ix Jul. 15 at 1:34 PM

$PURR in it, added.

1 · Reply

Donald_Kerabatsos Jul. 15 at 1:00 PM

0 · Reply

Donald_Kerabatsos Jul. 15 at 12:53 PM

$HYPE.X $PURR https://x.com/RyanWatkins_/status/2077238121880523027?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

0 · Reply

Olivia_Strickland Jul. 15 at 10:09 AM

2 · Reply

Thelonius_Stonk Jul. 15 at 9:59 AM

$PURR wutchn

2 · Reply

24_7Markets Jul. 15 at 9:46 AM

$HYPE.X $PURR $BTC.X Chart last 24 hours

1 · Reply

24_7Markets Jul. 15 at 9:45 AM

$HYPE.X $PURR $BTC.X

0 · Reply

Donald_Kerabatsos Jul. 15 at 3:06 AM

$HYPE.X $PURR She took her Viagra tonight…

0 · Reply

vu_jade Jul. 15 at 2:47 AM

$PURR $HYPE.X ADD

0 · Reply

Jackie_Treehorn Jul. 15 at 12:18 AM

$PURR

0 · Reply

24_7Markets Jul. 14 at 11:42 PM

$HYPE.X $PURR The smartest investors and traders on X are all in on Hyperliquid. X is always early, but the rest will catch on 🤝

0 · Reply

maikl_211 Jul. 14 at 11:17 PM

$PURR NO

0 · Reply

Donald_Kerabatsos Jul. 14 at 6:37 PM

$PURR https://hypestrat.xyz/dashboard

0 · Reply

Donald_Kerabatsos Jul. 14 at 6:30 PM

$PURR current mNAV still at .90 and crypto is warming up. Still massively undervalued even at HYPE $65

0 · Reply

WellWishes34 Jul. 14 at 3:59 PM

$PURR damn I'm glad I sold my put yesterday.

0 · Reply

FleeceWood_Mac Jul. 14 at 3:34 PM

$PURR $8 EOD

0 · Reply

FleeceWood_Mac Jul. 14 at 2:21 PM

$PURR cup and handle?

0 · Reply

FleeceWood_Mac Jul. 14 at 1:52 PM

$PURR bounce from yesterdays low is looking aggressive.

0 · Reply

Jackie_Treehorn Jul. 14 at 12:19 PM

$PURR probably mid to high 6a before the trend reverses. Keep an eye on $HYPE.X

2 · Reply

Mlanser Jul. 14 at 12:17 AM

$PURR .89mnav free 11% margin of safety. Im not saying buy it now but if you do plan on adding $PURR you definitely would want to be adding below 1mnav, especially at .89mnav. Once the broader crypto market starts kicking, $HYPE.X and $PURR will do extremely well.

1 · Reply

dark_gamma Jul. 13 at 7:48 PM

$PURR Options Heatmap - Crucial Levels Last: $7.11 Critical Resistance Points: $7.12 ($6.0M) | $7.58 ($5.7M) Essential Support Levels: $6.99 ($6.2M) | $6.83 ($6.4M) | $6.75 ($6.7M) Want to stay ahead of the market? Follow us for daily updates and in-depth analysis #PURR #Options #Trading #GEX #GammaExposure

0 · Reply

novelty Jul. 13 at 5:37 PM

$PURR down to 5.11-5.7 range by August then uppies resume

1 · Reply

Market Cap	1.03B
Revenue (ttm)	1.00M
Net Income (ttm)	-16.01M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	3.60
Profit Margin	-1,601.00%
Debt to Equity Ratio	0.00

Volume	9,923,399
Avg Vol	15,438,578
Day's Range	N/A - N/A
Shares Out	144.45M
Stochastic %K	17%
Beta	1.66
Analysts	Strong Sell
Price Target	$13.05